Payment overview · 2025
General Payments
$849.03
45 reported records · 14 companies
Healthcare provider profile · identity verified
Michael Barrett, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAMAR, SC · NPI 1588637771
Verified facts
What the public records show
CMS Open Payments records show Michael Barrett, MD received $849.03 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Nexletol.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Nexletol by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $182.31 | 21.5% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $114.45 | 13.5% | 6 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $101.43 | 11.9% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $97.53 | 11.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.91 | 9.3% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $74.31 | 8.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.63 | 7.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.54 | 5.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.44 | 2.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.94 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.95 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.19 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.77 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.63 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $849.03 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $145.79 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $114.45 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $101.43 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $97.53 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $79.39 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.91 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.91 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $74.31 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.47 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.78 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.78 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 100 |
| Eliquis | Apixaban | 191 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 47 |
| Januvia | Sitagliptin Phosphate | 156 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 49 |
| Omeprazole | Omeprazole | 129 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 50 |
| Tramadol Hcl | Tramadol Hcl | 120 | 29 |
| Gabapentin | Gabapentin | 119 | 40 |
| Metformin Hcl Er | Metformin Hcl | 114 | 33 |
| Metformin Hcl | Metformin Hcl | 112 | 34 |
| Spironolactone | Spironolactone | 110 | 34 |
| Ibuprofen | Ibuprofen | 109 | 31 |
| Potassium Chloride | Potassium Chloride | 109 | 40 |
| Colesevelam Hcl | Colesevelam Hcl | 104 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 36 |
| Lipitor | Atorvastatin Calcium | 86 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 18 |
| Welchol | Colesevelam Hcl | 84 | 35 |
| Allopurinol | Allopurinol | 83 | 18 |
| Furosemide | Furosemide | 82 | 31 |
| Donepezil Hcl | Donepezil Hcl | 80 | 12 |
| Farxiga | Dapagliflozin Propanediol | 80 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 27 |
| Ozempic | Semaglutide | 77 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 18 |
| Myrbetriq | Mirabegron | 73 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 20 |
| Losartan Potassium | Losartan Potassium | 71 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | suppressed |
| Norvasc | Amlodipine Besylate | 67 | 26 |
| Mounjaro | Tirzepatide | 66 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 23 |
| Trazodone Hcl | Trazodone Hcl | 60 | 12 |
| Montelukast Sodium | Montelukast Sodium | 55 | 23 |
| Colchicine | Colchicine | 53 | 14 |
| Ezetimibe | Ezetimibe | 53 | 21 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Meloxicam | Meloxicam | 51 | 20 |
| Sertraline Hcl | Sertraline Hcl | 51 | suppressed |
| Valsartan | Valsartan | 51 | 18 |
| Lisinopril | Lisinopril | 50 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 12 |
| Carvedilol | Carvedilol | 45 | 12 |
| Diovan | Valsartan | 43 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 13 |
| Ambien | Zolpidem Tartrate | 41 | suppressed |
| Neurontin | Gabapentin | 41 | 15 |
| Nexletol | Bempedoic Acid | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Tradjenta | Linagliptin | 40 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 14 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Protonix | Pantoprazole Sodium | 34 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 13 |
| Diazepam | Diazepam | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Azithromycin | Azithromycin | 26 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Plavix | Clopidogrel Bisulfate | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 24 | 24 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Toprol Xl | Metoprolol Succinate | 24 | 12 |
| Crestor | Rosuvastatin Calcium | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Finasteride | Finasteride | 22 | suppressed |
| Lasix | Furosemide | 22 | 11 |
| Linzess | Linaclotide | 22 | suppressed |
| Nexium | Esomeprazole Magnesium | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Celebrex | Celecoxib | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Lyrica | Pregabalin | 18 | suppressed |
| Xanax | Alprazolam | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Zestril | Lisinopril | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 11 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Zetia | Ezetimibe | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Singulair | Montelukast Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cymbalta | Duloxetine Hcl | 13 | suppressed |
| Flomax | Tamsulosin Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Avapro | Irbesartan | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Lopressor | Metoprolol Tartrate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Rhopressa | Netarsudil Mesylate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lexapro | Escitalopram Oxalate | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $849.03 · 45 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, QULIPTA, REPATHA, REXULTI, UBRELVY, VOQUEZNA, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error